help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Molecular Endocrinology, doi:10.1210/me.2005-0531
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data File
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, M. Y.
Right arrow Articles by Kraus, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, M. Y.
Right arrow Articles by Kraus, W. L.
Molecular Endocrinology 20 (7): 1479-1493
Copyright © 2006 by The Endocrine Society

Acetylation of Estrogen Receptor {alpha} by p300 at Lysines 266 and 268 Enhances the Deoxyribonucleic Acid Binding and Transactivation Activities of the Receptor

Mi Young Kim, Eileen M. Woo, Yee Ting Esther Chong, Daria R. Homenko and W. Lee Kraus

Department of Molecular Biology and Genetics (M.Y.K., Y.T.E.C., D.R.H., W.L.K.), Cornell University, Ithaca, New York 14853; Laboratory of Chromatin Biology and Epigenetics (E.M.W.), The Rockefeller University, and Department of Pharmacology (W.L.K.), Weill Medical College of Cornell University, New York, New York 10021

Address all correspondence and requests for reprints to: W. Lee Kraus, Department of Molecular Biology and Genetics, Cornell University, 465 Biotechnology Building, Ithaca, New York 14853. E-mail: wlk5{at}cornell.edu.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Using a variety of biochemical and cell-based approaches, we show that estrogen receptor {alpha} (ER{alpha}) is acetylated by the p300 acetylase in a ligand- and steroid receptor coactivator-dependent manner. Using mutagenesis and mass spectrometry, we identified two conserved lysine residues in ER{alpha} (Lys266 and Lys268) that are the primary targets of p300-mediated acetylation. These residues are acetylated in cells, as determined by immunoprecipitation-Western blotting experiments using an antibody that specifically recognizes ER{alpha} acetylated at Lys266 and Lys268. The acetylation of ER{alpha} by p300 is reversed by native cellular deacetylases, including trichostatin A-sensitive enzymes (i.e. class I and II deacetylases) and nicotinamide adenine dinucleotide-dependent/nicotinamide-sensitive enzymes (i.e. class III deacetylases, such as sirtuin 1). Acetylation at Lys266 and Lys268, or substitution of the same residues with glutamine (i.e. K266/268Q), a residue that mimics acetylated lysine, enhances the DNA binding activity of ER{alpha} in EMSAs. Likewise, substitution of Lys266 and Lys268 with glutamine enhances the ligand-dependent activity of ER{alpha} in a cell-based reporter gene assay. Collectively, our results implicate acetylation as a modulator of the ligand-dependent gene regulatory activity of ER{alpha}. Such regulation is likely to play a role in estrogen-dependent signaling outcomes in a variety of estrogen target tissues in both normal and pathological states.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
THE GENE-REGULATORY ACTIONS of estrogens are mediated through two nuclear estrogen receptor (ER) proteins, ER{alpha} and ERß, which belong to the nuclear receptor superfamily (1, 2, 3). ERs bind estrogens with high affinity and function as ligand-regulated transcription factors to control global patterns of gene expression. ER{alpha} and ERß have unique, but overlapping, patterns of expression in a variety of estrogen target tissues, including mammary glands, uterus, and bone (4, 5, 6). In addition, the two ERs may exhibit distinct gene-regulatory activities under certain promoter and cell contexts (7, 8, 9, 10, 11, 12, 13, 14, 15).

ER{alpha} and ERß share a conserved structural and functional organization, including the following: 1) an amino-terminal A/B region containing a transcriptional activation function (AF-1), 2) a DNA-binding domain (DBD), and 3) a carboxyl-terminal ligand-binding domain (LBD) containing a second transcriptional activation function (AF-2) (see Fig. 2BGo) (1, 3). In addition to these canonical nuclear receptor domains, recent studies have also begun to characterize the C-terminal extension (CTE) of the ER{alpha} and ERß DBDs (amino acids 251–288 and 170–207, respectively), which plays a role in regulating the DNA-binding activities of the receptors (16, 17). The coordinated actions of the aforementioned ER functional domains allow for precisely controlled signal-regulated transcription in response to both natural and synthetic ER ligands.


Figure 2
View larger version (32K):
[in this window]
[in a new window]
  		Fig. 2. The ER{alpha} DNA Binding Domain Is the Major Target for E2- and SRC-Dependent Acetylation by p300

A, The 29 lysine residues in ER{alpha} are listed by the ER{alpha} domain in which they appear. B, Schematic diagram of the ER{alpha} deletion and point mutants used in the ER{alpha} acetylation assays. The wild-type (Wt), K302/303R, {Delta}AB, and {Delta}DBD ER{alpha} are FLAG-tagged, whereas the LBD polypeptides (i.e. 282–595 and 282–420) are GST-tagged. The locations of Lys302 and Lys303 are indicated by white dots. C, Acetylation assays with the point and deletion mutants shown in B. Acetylation assays were performed as described for Fig. 1BGo. GST-SRC2(RID/PID) was added as indicated. The reactions were analyzed by SDS-PAGE with subsequent fluorography. To allow direct comparisons of acetylation levels, equal molar (not equal mass) amounts of each protein were used, as verified by staining with Coomassie brilliant blue R-250.

 
The binding of agonistic ligands by ER{alpha} and ERß promotes a conformational change in the receptor LBD that allows the receptor to interact directly or indirectly with a diverse set of coregulatory proteins (1, 3). These include members of the steroid receptor coactivator (SRC) family (i.e. SRC1, -2, and -3), which function primarily as bridging factors to recruit other coregulators (18, 19, 20), including a diverse set of protein-modifying enzymes (e.g. acetylases, methyltransferases, kinases) (21, 22). p300 and its paralog cAMP response element binding protein-binding protein (CBP) are the two best characterized mammalian acetylases. They function as coregulators for a variety of transcription factors, including ERs and other nuclear receptors (23, 24, 25). p300 and CBP are recruited to ER{alpha} and ERß in a ligand-dependent manner via interactions with SRC proteins. During an estrogen-dependent transcriptional response, p300 and CBP can acetylate nucleosomal histones to alter chromatin structure and function (19, 22), as well as components of the transcription complex to alter transcriptional activity (see below). A variety of deacetylases, including trichostatin A (TSA)-sensitive enzymes (i.e. class I and II deacetylases, such as histone deacetylase 1) and nicotinamide adenine dinucleotide (NAD+)-dependent/nicotinamide-sensitive enzymes [i.e. class III deacetylases, such as sirtuin 1 (SIRT1)], also function as coregulators and can reverse the protein acetylation reactions catalyzed by acetylases (26, 27, 28, 29).

A number of recent studies have shown that acetylation is an important covalent posttranslational modification for regulating the activity of transcription-related factors, including p53, SRC3 (also known as ACTR), nuclear factor-{kappa}B p65, and poly(ADP-ribose) polymerase-1 (30, 31, 32, 33, 34, 35, 36, 37, 38, 39). Interestingly, different acetylases (e.g. p300/CBP vs. p300/CBP-associated factor) have different substrate preferences as demonstrated by the fact that some factors can be acetylated by one but not the other (35, 36, 38, 40). With regard to modulating the activity of transcription-related factors, the consequence of acetylation may be either transcriptional activation or inhibition. Acetylation of transcription-related factors can increase their transcriptional activity by the following: 1) enhancing DNA binding activity, 2) stimulating interactions with positive transcriptional regulators, such as chromatin remodeling factors or coactivators, 3) inhibiting interactions with negative regulators, resulting in a loss of transcription repression, 4) increasing the stability of the factors, and 5) altering subcellular localization (35, 36, 38, 40). Likewise, acetylation may inhibit the activity of transcription-related factors by reducing binding to DNA or chromatin, as well as reducing protein-protein interactions required for transcriptional activation (35, 36, 38, 40). Thus, the specific biochemical effects of acetylation are varied and differ with each target protein.

In the studies described herein, we show that ER{alpha}, but not ERß, is a target for acetylation by p300. Using a variety of biochemical and cell-based assays, we have identified the sites of acetylation, and explored the mechanisms and functional consequences of p300-mediated acetylation on ER{alpha} activity. Collectively, our results implicate acetylation as modulator of the ligand-dependent gene regulatory activity of ER{alpha}.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Human ER{alpha} Is Acetylated by p300 and Deacetylated by TSA- and Nicotinamide-Sensitive Deacetylases
To examine the acetylation of human ER{alpha} by p300, we used an in vitro acetylation assay with [3H]acetyl coenzyme A (acetyl CoA) and the following purified recombinant proteins: ER{alpha}, p300, and glutathioneS-transferase (GST)-fused SRC2(RID/PID), which contains the receptor interaction domain (RID) and p300/CBP interaction domain (PID) of SRC2 (Fig. 1AGo). With this assay, we showed previously that SRCs play a key role in the targeted acetylation of nucleosomal core histones by p300, functioning as a bridging factor between p300 and 17ß-estradiol (E2)-bound ER{alpha} (Ref. 41 and Fig. 1BGo, bottom). Interestingly, these same interactions also promote the acetylation of ER{alpha} (Fig. 1BGo, top), indicating that interactions among agonist-bound ER{alpha}, SRC, and p300 are required for efficient acetylation of ER{alpha} by p300 (see also supplemental Fig. 1Go, published as supplemental data on The Endocrine Society’s Journals Online web site at http://mend.endojournals.org). SRC2(RID/PID), which lacks the putative SRC acetylase domain (18, 21), was unable to promote the acetylation of ER{alpha} in the absence of p300 (data not shown).


Figure 1
View larger version (25K):
[in this window]
[in a new window]
  		Fig. 1. ER{alpha} Is Acetylated by p300 and Deacetylated by TSA- and Nicotinamide-Sensitive Deacetylases

A, SDS-PAGE analyses of purified recombinant ER{alpha}, GST-SRC2(RID/PID), p300, and SIRT1 stained with Coomassie brilliant blue R-250. Size markers in kilodaltons are shown. The asterisk for the GST-SRC2(RID/PID) sample indicates a major breakdown product with minor breakdown products below. B, p300 acetylates ER{alpha} and nucleosomal core histones in an E2- and SRC-dependent manner. ER{alpha} and salt-dialyzed chromatin were incubated with p300 in the presence of GST-SRC2(RID/PID), E2, and [3H]acetyl CoA. The reactions were analyzed by SDS-PAGE with subsequent fluorography. C, ER{alpha} is deacetylated by TSA- and nicotinamide-sensitive deacetylases. [3H]AcER{alpha} was incubated with HeLa cell nuclear extract (HeLa NE) in the presence or absence of NAD+, TSA, or nicotinamide as indicated. The reactions were analyzed by SDS-PAGE with subsequent fluorography. D, ER{alpha} is deacetylated by the NAD+-dependent deacetylase SIRT1. The assays were set up as in C except that purified recombinant SIRT1 was used in place of the HeLa cell NE.

 
Next, we examined whether the p300-dependent acetylation of ER{alpha} can be reversed by native deacetylases present in a HeLa cell nuclear extract (HNE). Immobilized [3H]acetylated ER{alpha} was incubated with HNE, which contains a variety of deacetylases including TSA-sensitive enzymes (i.e. class I and II deacetylases) and NAD+-dependent/nicotinamide-sensitive enzymes (i.e. class III deacetylases, such as SIRT1) (26, 27, 28, 29). As shown in Fig. 1CGo, incubation with HNE dramatically reduced the acetylation of ER{alpha} (compare lanes 1 and 2). The addition of TSA inhibited deacetylation of ER{alpha} by the HNE (lane 3), indicating that one or more class I/II deacetylases present in the HNE can deacetylate ER{alpha}. The addition of NAD+ in the presence of TSA (i.e. under conditions in which class I/II deacetylases were inhibited) also resulted in the deacetylation of ER{alpha} (compare lanes 3 and lane 4). The effect of NAD+ was blocked by the addition of nicotinamide (lane 5), indicating that one or more class III deacetylases present in the HNE, such as SIRT1, can deacetylate ER{alpha}. To explore this last result further, we performed a similar set of experiments using purified recombinant SIRT1 (Fig. 1AGo) in place of the HNE. As shown in Fig. 1DGo, SIRT1 without added NAD+ had no effect on the acetylation of ER{alpha} (compare lanes 1 and 2), whereas SIRT1 in the presence of NAD+ was a potent deacetylase of ER{alpha} (lane 3). The deacetylation of ER{alpha} by SIRT1 plus NAD+ was inhibited by nicotinamide (lane 4), but not by TSA (lane 5). Taken together, these results indicate that the acetylation of ER{alpha} by p300 can be reversed by native TSA- and nicotinamide-sensitive deacetylases, including SIRT1.

Initial Identification of Lys268 and Lys266 as Sites of Acetylation in ER{alpha}
Full-length ER{alpha} contains 29 lysine residues that are potential sites of acetylation by p300: four in the A/B region, 10 in the DBD, and 15 in the LBD (for the purposes of this study, the domains have the boundaries defined in Fig. 2AGo). To identify the lysine residues in ER{alpha} that are acetylated by p300, we used deletion mutants (Fig. 2Go, B and C), point mutants (Fig. 3Go), and an unbiased quantitative mass spectrometry approach (Fig. 4Go). ER{alpha} deletion mutants lacking either the A/B region (i.e. ER{alpha}{Delta}AB), DBD (i.e. ER{alpha}{Delta}DBD), or both the A/B region and the DBD [i.e. GST-LBD(282–595)] (Fig. 2BGo) were assayed for E2- and SRC-dependent acetylation by p300 in the presence of [3H]acetyl CoA. Importantly, all three of these receptor deletions contain intact LBDs and SRC interaction domains, because efficient acetylation of ER{alpha} requires the binding of E2 and SRC (Fig. 1BGo and supplemental Fig. 1). Note that, for these assays, we used equal molar amounts of the purified receptor proteins, as opposed to equal mass amounts (Fig. 2CGo, bottom), so that the relative number of [3H]acetyl groups added per mole of protein could be assessed. The ER{alpha} deletion mutant lacking the A/B region (i.e. ER{alpha}{Delta}AB) showed a modest reduction in E2- and SRC-dependent acetylation by p300, whereas the ER{alpha} deletion mutants lacking the DNA binding domain [i.e. ER{alpha}{Delta}DBD and GST-LBD(282–595)] showed a dramatic reduction in acetylation (Fig. 2CGo, top). These results suggested that the DBD is the major target for acetylation by p300. This result was confirmed by the independent approaches described below.


Figure 3
View larger version (41K):
[in this window]
[in a new window]
  		Fig. 3. Mutation of Lys266 and Lys268 in ER{alpha} Reduces Acetylation by p300

A, Acetylation assays with ER{alpha} lysine mutants. Purified FLAG-tagged wild-type and Lys to Arg single-point mutant ER{alpha}s were assayed for acetylation by p300 in the presence of GST-SRC2(RID/PID) and E2 as described for Fig. 1BGo. Top, SDS-PAGE analysis of the purified ER{alpha} proteins with subsequent staining using Coomassie brilliant blue R-250 to confirm equal protein amounts. Size markers in kilodaltons are shown. Bottom, Summary of the results from the acetylation assays. The ER{alpha} bands were excised from the gels after fluorography and quantified by liquid scintillation counting. The acetylation level of each lysine point mutant was expressed relative to wild type. Each bar represents the mean + SEM from at least three different experiments. B, Acetylation assays with Lys to Arg 266/268 double-point mutant ER{alpha}s. Wild-type and mutant ER{alpha}s were assayed for acetylation by p300 in the presence of GST-SRC2(RID/PID) and E2 as described for Fig. 1BGo. Top, SDS-PAGE analysis of the purified ER{alpha} proteins with subsequent fluorography. Bottom, The same gel stained using Coomassie brilliant blue R-250 to confirm equal protein amounts.

 

Figure 4
View larger version (23K):
[in this window]
[in a new window]
  		Fig. 4. Quantitative Mass Spectrometric Analysis of ER{alpha} Acetylation by p300

A, Schematic diagram of the quantitative mass spectrometric procedure for determining site-specific ER{alpha} acetylation levels. B, Quantitative mass spectrometric determination of SRC- and E2-dependent acetylation by p300 of peptide 264–269 from trypsin-digested full-length wild-type or K268Q mutant ER{alpha}. The ER{alpha}s were assayed for acetylation by p300 in the presence of GST-SRC2(RID/PID) and E2 as described for Fig. 1BGo and then subjected to quantitative MALDI-QqTOF spectrometry as described in A. The data are expressed as amount of acetylated 264–269 peptide (i.e. AcK) relative to the total amount of 264–269 peptide in the reaction (i.e. AcK plus DAcK). As indicated in Table 1Go, K268 is the major site (~95%) of single acetylation in the 264–269 peptide. In the K268Q mutant, all of the acetylation of the 264–269 peptide is at K266.

 
To determine the sites of acetylation more precisely, we individually changed the 10 lysine residues in the DBD and the four lysine residues in the A/B region to arginine, an amino acid that has a positively charged side chain like lysine, but cannot be acetylated. The 14 lysine to arginine (K{Rightarrow}R) point mutant ER{alpha}s were expressed and purified as recombinant proteins, and then assayed for E2- and SRC-dependent acetylation by p300 vs. wild-type ER{alpha}. Of the 14 K{Rightarrow}R point mutants tested, only two showed a reduction in acetylation: K268R (~50% reduction) and K266R (~20% reduction) (Fig. 3AGo and data not shown). When both Lys266 and Lys268 were mutated, there was a dramatic (>90%) reduction in acetylation (Fig. 3BGo). These results provided a first indication that Lys268 and Lys266, both of which are in the CTE of the DBD (17), are major and minor targets, respectively, for E2- and SRC-dependent acetylation by p300.

Confirmation by Mass Spectrometry of Lys268 and Lys266 as Sites of Acetylation in ER{alpha}
To confirm the sites of acetylation in ER{alpha} using an independent and unbiased assay, we used the quantitative mass spectrometry approach outlined in Fig. 4AGo (42). In vitro acetylation reactions with full-length ER{alpha} plus SRC, p300, and E2 were performed in the absence or presence of cold acetyl CoA. After enzymatic acetylation of the lysine residues in ER{alpha} specifically targeted by p300, all of the remaining unacetylated lysine residues were chemically acetylated using deuterated-acetic anhydride. The modified ER{alpha} protein was then digested with trypsin. The resulting peptides contained light acetyl groups (AcK) on lysines acetylated by p300 and heavy (deuterated) acetyl groups (DAcK) on all other lysines. The mass difference of 3 Da between AcK and DAcK on the peptides was visualized by matrix-assisted laser desorption/ionization (MALDI)-quadrupole-quadrupole-time of flight (QqTOF) mass spectrometry (43). The percent acetylation of the chemically identical, isotopically distinct peptides (i.e. heavy vs. light) was calculated directly from ratios of the intensities of the monoisotopic peaks (42).

The mass spectrometry approach provided good coverage of the lysine residues in the A/B region, DBD, and hinge region spanning amino acids 1 through 298 (12 of the 14 lysine residues in this region were detected and quantified; Lys48 and Lys257 were in peptides that were not observed by the mass spectrometry approach) (supplemental Table 1). Coverage in the LBD spanning amino acids 299 through 595 was less complete (only eight of the 15 lysine residues in this region were detected and quantified) (supplemental Table 1). However, the results in Fig. 2CGo indicate that the LBD is not a major target of acetylation by p300. Furthermore, when taken in combination, the three analytical approaches that we used (i.e. deletion mutants, point mutants, and mass spectrometry) yielded complete coverage of all 29 lysine residues in ER{alpha} (supplemental Table 1).

Three of the detectable tryptic peptides from the mass spectrometry analysis had quantifiable levels of acetyl CoA-dependent acetylation (expressed as a percentage of the total amount of each peptide present in the reaction) (Table 1Go). The acetylated peptides spanned the following residues in ER{alpha}: 1) 244–256, containing Lys244 and Lys252, 2) 264–269, containing Lys266 and Lys268, and 3) 288–300, containing Lys299 (Table 1Go). The 264–269 peptide had approximately 3- and 6-fold more total p300-dependent acetylation than the 244–256 and 288–300 peptides, respectively (Table 1Go; 31.5 ± 0.9 vs. 11.1 ± 0.7 and 4.5 ± 0.6%, respectively), indicating that the 264–269 peptide contains the major target for E2- and SRC-dependent acetylation by p300. These results fit well with our mutagenesis experiments, which identified Lys268 and Lys266 as major and minor sites of acetylation, respectively. Based on these results, we focused on Lys266 and Lys268 and explored the E2- and SRC-dependent acetylation of these residues by p300 in more detail.


View this table:
[in this window]
[in a new window]
  		Table 1. Quantitative Mass Spectrometric Analysis of ER{alpha} Reveals Lys268 as a Major Site of Acetylation by p300

 
Mass spectrometry/mass spectrometry (MS/MS) analysis using MALDI-ion trap mass spectrometry was used to quantify the acetylation of the two individual lysine residues in the 264–269 peptide (i.e. Lys266 and Lys268). For the singly acetylated species of the 264–269 peptide, >95% of the acetylation was on Lys268 (Table 1Go and data not shown). In addition, the singly acetylated (i.e. primarily Ac-Lys268) species of the 264–269 peptide was present at approximately 3- to 4-fold more than the doubly acetylated (i.e. Ac-Lys266 plus Ac-Lys268) species (Fig. 4BGo and Table 1Go). Furthermore, mutation of Lys268 to an unacetylatable residue (i.e. glutamine, Q) reduced the amount of both single and double acetylation of the 264–269 peptide (Fig. 4BGo), even though a dramatic (~10-fold) compensatory increase in the acetylation of Lys266 was observed, from ~1% of the total peptide for wild-type ER{alpha} (Table 1Go, see Single Acetylation column for K266) to ~10% of the total peptide for the K268Q mutant (Fig. 4BGo). Further MS/MS analyses demonstrated that both single and double acetylation of the 264–269 peptide occurred efficiently only when acetylation of the full-length ER{alpha} was carried out in the presence of E2 and GST-SRC2(RID/PID) (Fig. 4BGo). Collectively, the mass spectrometry data support the conclusions that 1) Lys268 is the major site of E2- and SRC-dependent acetylation by p300 and 2) Lys266 is a minor site whose acetylation can be increased by mutation or prior acetylation of Lys268. These conclusions fit well with the conclusions from the mutagenesis studies described above.

Lys302 and Lys303 Are Not Major Sites of Acetylation by p300 in Full-Length ER{alpha}
Results from a recent study by Wang et al. (44) showed that Lys302 and Lys303 in an isolated fragment of ER{alpha} (i.e. amino acids 282–420) can be acetylated by p300 in the absence of E2 and SRC. We examined whether these same sites might be potential sites of acetylation in full-length ER{alpha} by mutating both sites to arginine, a residue that cannot be acetylated. We found no difference in the acetylation of wild-type or K302/303R ER{alpha} by p300 with or without E2 or GST-SRC2(RID/PID) (Figs. 2CGo and 3AGo; data not shown), indicating that Lys302 and Lys303 are not targets for acetylation by p300 in full length of ER{alpha}. These results were confirmed in our mass spectrometry analysis, which showed no detectable acetylation on Lys302 and Lys303 (Table 1Go, supplemental Table 1, and data not shown). Interestingly, a fragment of ER{alpha} containing the entire LBD including Lys302 and Lys303 (i.e. amino acids 282–595) was not acetylated by p300 (Fig. 2CGo, lanes 9 and 10), yet the smaller fragment used by Wang et al. (44) (i.e. amino acids 282–420) was acetylated (Fig. 2CGo, lanes 11 and 12). These results suggest that Lys302 and Lys303 are cryptic residues that are not normally accessible to p300 in full-length ER{alpha}. Truncation of the LBD (as in the 282–420 fragment) presumably disrupts the secondary and tertiary structure of the LBD, which could cause Lys302 and Lys303 to become exposed and accessible to acetylation by p300. Taken together, our results indicate that Lys302 and Lys303 are not major sites of acetylation by p300 in full-length ER{alpha}.

Lys268 and Lys266 Are Conserved across Species
Alignment of human ER{alpha} with the ER{alpha}s from a variety of other species shows that Lys266 and Lys268 have been conserved throughout evolution, at least from amphibians through mammals (Fig. 5AGo). Furthermore, three of the four fish species examined have at least one lysine in the same position as Lys266 and Lys268, or within one residue (Fig. 5AGo). Although alignment of human ER{alpha} with other human nuclear receptors is difficult for the CTE due to low sequence conservation, the alignment can be fixed at the most carboxyl-terminal conserved cysteine residue in the second zinc finger of the DBD (Cys240 for ER{alpha}; Fig. 5BGo). Such an analysis reveals that almost all non-orphan nuclear receptors have at least one, but typically two or more, and as many as six, lysine residues located in the amino-terminal portion of the CTE (+11 to +32 relative to the aforementioned conserved cysteine residue). This region includes the three lysine residues in the androgen receptor (AR) that are acetylated by p300/CBP (Lys630, Lys632, and Lys633) (45, 46, 47). These lysine-rich regions may be targeted for acetylation in other receptors as well. Interestingly, ERß lacks lysine residues homologous to Lys266 and Lys268 in ER{alpha} (Fig. 5BGo), fitting well with our observation that ERß is not acetylated by p300 under the same conditions that lead to acetylation of ER{alpha} (data not shown).


Figure 5
View larger version (62K):
[in this window]
[in a new window]
  		Fig. 5. Alignment of the Amino Acid Sequences Surrounding Lys266 and Lys268 in Human ER{alpha} with Corresponding Regions from Other ER{alpha}s and Other Nuclear Receptors

Sequence alignment of the CTE of the human ER{alpha} DBD with the corresponding region of ERs from other species and other nuclear receptors. The alignments were anchored at the last conserved cysteine residue in the second zinc finger of the DBD (first C in each row). The boxed region demarcates the amino-terminal portion of the CTE [i.e. those residues located within +11 to +32 of the aforementioned cysteine residue; note that the full CTE, as defined by Melvin et al. (17 ), extends to +47]. Asterisks indicate residues that are conserved in all of the receptors shown. A, Alignment of ER{alpha}s. The lysine residues (K) highlighted in bold correspond to Lys266 and Lys268 in human ER{alpha}. B, Alignment of human nuclear receptors. All of the lysine residues (K) in the boxed region are highlighted in bold. K266 and K268 of ER{alpha}, and K630, K632, and K633 of AR are underlined.

 
Lys268 and Lys266 of ER{alpha} Are Acetylated in Vivo
Next, we determined whether Lys266 and Lys268 are bona fide acetylation sites in vivo. For these studies, we generated an antiserum that specifically recognizes acetylated Lys266/Lys268 ER{alpha} (AcK266/268-ER{alpha}) using a doubly acetylated peptide antigen spanning amino acids 263 through 273 of human ER{alpha}. Due to sequence conservation among mammalian ER{alpha}s (Fig. 5AGo), this antiserum should recognize similarly acetylated ER{alpha} from most, if not all, mammalian species. As shown in the Western blots in Fig. 6AGo, this antiserum specifically recognizes purified wild-type ER{alpha} that has been acetylated by p300 (middle panels), but not unacetylated wild-type ER{alpha} (left panels). Furthermore, this antiserum does not recognize K266/268Q ER{alpha} (right panels) or K268Q ER{alpha} (data not shown) that has been incubated with p300 under conditions that lead to the acetylation of wild-type ER{alpha} (i.e. +acetyl CoA, +E2, +SRC). These results, as well as the assays described below, demonstrate that this antiserum specifically recognizes acetylated K266/268 ER{alpha}.


Figure 6
View larger version (42K):
[in this window]
[in a new window]
  		Fig. 6. Lys266 and Lys268 of ER{alpha} Are Acetylated in Vivo

A, Characterization of the AcK266/268-ER{alpha} antibody. Increasing amounts (10 ng to 300 ng) of purified acetylated or unacetylated wild-type or K266/268Q mutant ER{alpha}s were subjected to SDS-PAGE, followed by Western blotting with either anti-ER{alpha} antibody or anti-AcK266/268-ER{alpha} antibody. B, Schematic diagram of the in vivo ER{alpha} acetylation assay. NA, Nicotinamide. C and D, Analysis of ER{alpha} acetylation in 231/ER{alpha} (C) and 293T cells transiently transfected with an ER{alpha} expression vector (D). Assays were performed as outlined in B. The immunoprecipitated material was deacetylated by the addition of recombinant SIRT1 and NAD+ as indicated to demonstrate specificity of the AcK266/268-ER{alpha} antibody for the acetylated form of ER{alpha}.

 
Once we verified the specificity of our antiserum, we carried out in vivo acetylation assays by using the experimental scheme illustrated in Fig. 6BGo. Briefly, FLAG-tagged ER{alpha} was immunoprecipitated from one of two cell lines (231/ER{alpha} cells, which stably express FLAG-tagged ER{alpha}, or transfected 293T cells, which transiently express FLAG-tagged ER{alpha}). Note that the cells were treated with TSA and nicotinamide before collection to block the actions of deacetylases during the experiment. In the absence of these treatments, the acetylation of ER{alpha} was dramatically reduced (data not shown), suggesting that deacetylation of the receptor occurs rapidly in vivo. The immunoprecipitates were then analyzed for acetylated ER{alpha} using the acetylated Lys266/Lys268 ER{alpha} antiserum described above. To demonstrate acetylation dependence for the observed signal, the immunoprecipitated material was deacetylated by the addition of recombinant SIRT1 plus NAD+ in some cases before Western blotting.

In 231/ER{alpha} cells, we observed basal acetylation of Lys266/Lys268 that was increased about 2- to 3-fold in the presence of E2 (Fig. 6CGo, compare lanes 1 and 2). As expected, the signal for acetylated Lys266/Lys268 ER{alpha} in the immunoprecipitated material was lost upon incubation with SIRT1 plus NAD+ before Western blotting (compare lanes 3 and 4). These results indicate that ER{alpha} from a well-characterized estrogen-responsive cell line that stably expresses the receptor (for example, see Refs. 48 and 49) is acetylated at Lys266 and Lys268, and that the level of acetylation can be modulated by E2. Next, we used transient expression of FLAG-tagged ER{alpha} in 293T cells, which are ER{alpha} negative, so that we could compare the acetylation of wild-type ER{alpha} with an unacetylatable Lys266/Lys268 mutant (i.e. K266/268R) in vivo. Wild-type ER{alpha} immunoprecipitated from the transfected 293T cells was acetylated at Lys266/Lys268 (Fig. 6DGo, lane 1). Again, as expected, the signal for acetylated Lys266/Lys268 ER{alpha} was lost upon incubation of the immunoprecipitated material with SIRT1 plus NAD+ before Western blotting (lane 2). In contrast to wild-type ER{alpha}, no acetylation of the K266/268R mutant was observed (Fig. 6DGo, lanes 3 and 4). Together, these cell-based studies using an antiserum that specifically recognizes acetylated Lys266/Lys268 ER{alpha} clearly demonstrate that ER{alpha} is acetylated at Lys266 and Lys268 in vivo.

Interestingly, similar experiments using an antiserum that specifically recognizes ER{alpha} singly acetylated at Lys266 (AcK266-ER{alpha}) or Lys268 (AcK268-ER{alpha}) failed to detect acetylated ER{alpha} in the immunoprecipitated material from 231/ER{alpha} cells and transfected 293T cells (data not shown). These results suggest that, although the AcK268-ER{alpha} species may predominate in the in vitro reaction (Table 1Go), the AcK266/268-ER{alpha} species predominates in cells.

Acetylation or Mutation of ER{alpha} at Lys266/Lys268 Does Not Affect E2 Binding, Interaction with SRC2, or Subcellular Localization of ER{alpha}
Our initial studies using 1) a transcriptionally inactive ER{alpha} mutant defective in SRC binding (i.e. L540Q) and 2) a set of previously characterized polypeptide inhibitors that block ER{alpha}-SRC and SRC-p300/CBP interactions showed that acetylation of ER{alpha} by p300 correlates with E2-dependent transcriptional activation (supplemental Fig. 1Go). To explore the possible effects of acetylation on the activities of ER{alpha} in more detail, we performed a number of functional assays to examine ligand binding (supplemental Fig. 2A), ER{alpha}-SRC2 interactions (supplemental Fig. 2B), subcellular localization (supplemental Fig. 2C), DNA binding (Fig. 7Go), and transactivation (Fig. 8Go). For these assays, we used a set of Lys266/Lys268 double mutants in which the lysine residues were changed to arginine (R, which has a positively charged side chain and mimics unacetylated lysine) or glutamine (Q, which has a neutral side chain and mimics acetylated lysine). As shown in Fig. 3BGo, ER{alpha} mutants harboring these changes (i.e. K266/268R and K266/268Q) showed a dramatic reduction in acetylation by p300 in vitro compared with wild-type ER{alpha} (see also Fig. 6Go, A and D). Our results indicate that acetylation or mutation of ER{alpha} at Lys266/Lys268 does not appreciably affect E2 binding, interaction with SRC2, or subcellular localization of ER{alpha} (supplemental Fig. 2).


Figure 7
View larger version (34K):
[in this window]
[in a new window]
  		Fig. 7. Acetylated ER{alpha} and K266/268Q ER{alpha} Exhibit Increased DNA Binding Activity

A, Acetylation of ER{alpha} by p300 in vitro increases ER{alpha} DNA binding activity in EMSAs. Aliquots of purified ER{alpha} were incubated with p300, GST-SRC2(RID/PID), and E2 in the absence (i.e. no acetylation) or presence (i.e. acetylation) of unlabeled acetyl CoA as indicated. Aliquots of the reactions were subjected to Western blotting using an acetyl lysine antibody (top) or an ER{alpha} antibody (middle), or analyzed by EMSA (bottom). The fold increase of ER{alpha}:ERE complex formation upon acetylation is indicated. B, Changing the p300 acetylation sites in ER{alpha} from Lys to Arg (which mimics unacetylated Lys) inhibits acetylation-dependent increases in the DNA binding activity of ER{alpha} in EMSAs. The assays were set up as described for A using wild-type, K180R, and K266/268R mutant ER{alpha}s, followed by an EMSA. The fold increase of ER{alpha}:ERE complex formation upon acetylation is indicated. C, Changing Lys266 and Lys268 in ER{alpha} to Gln (Q) increases the DNA binding activity of ER{alpha} in EMSAs. The EMSAs were set up using increasing amounts of unacetylated wild-type, K180R, and K266/K268Q ER{alpha}s. The DNA binding activities of the mutant ER{alpha}s were calculated relative to wild-type ER{alpha}. Each bar represents the mean + SEM from at least three separate determinations.

 

Figure 8
View larger version (18K):
[in this window]
[in a new window]
  		Fig. 8. K266/268Q ER{alpha}, But Not K266/268R ER{alpha}, Exhibits Increased Transactivation Activity in Cells

A, The transactivation activities of wild-type and K266/268 mutant ER{alpha}s were assessed by transient transfection reporter gene assays. HeLa cells were transfected with expression vectors for wild-type or K266/268 mutant ER{alpha}s, pGL3–2ERE-pS2-Luc (an E2-responsive luciferase reporter vector), and a ß-galactosidase expression vector (used as an internal control). Transfected cells were treated with 10 nM E2 for 18 h before collection for determination of luciferase and ß-galactosidase activities. The luciferase activity in each sample was normalized to ß-galactosidase activity. Each bar represents the mean + SEM from at least three separate determinations. B, Expression levels of wild-type and K266/268 mutant ER{alpha}s in the transfected HeLa cells. Extracts from the transfected HeLa cells described in A were analyzed by Western blotting for ER{alpha}. The samples were normalized for ß-galactosidase activity and total protein amount.

 
Acetylated ER{alpha} and K266/268Q ER{alpha} Exhibit Increased DNA Binding Activity
Next, we examined the effects of acetylation on ER{alpha} DNA binding activity by using EMSAs. In our initial assays, purified wild-type ER{alpha} was incubated with p300 in the presence of E2 and GST-SRC2(RID/PID) with or without unlabeled acetyl CoA to generate acetylated or unacetylated ER{alpha}, respectively. Aliquots of each reaction were subjected to Western blotting using the following: 1) an anti-acetyl-lysine antibody to confirm the acetylation of ER{alpha}, which occurred only in the presence of acetyl CoA, as expected (Fig. 7AGo, top) and 2) an anti-ER{alpha} antibody, which detected total ER{alpha} (Fig. 7AGo, middle). Another aliquot from each reaction was used in EMSAs with a 32P-labeled double-stranded DNA probe containing an ERE sequence (Fig. 7AGo, bottom). Interestingly, acetylated ER{alpha} showed an approximate 4-fold increase in DNA binding activity compared with mock acetylated ER{alpha} (i.e. reaction without acetyl CoA). This effect was blocked by mutation of Lys266/Lys268 to arginine, but not Lys180, which was used as a control (Fig. 7BGo). Interestingly, mutation of Lys266/Lys268 to glutamine (i.e. K266/268Q), but not arginine (i.e. K266/268R), increased DNA binding activity of unacetylated ER{alpha} by about 5-fold (Fig. 7CGo). Thus, ER{alpha} DNA binding activity increases as the side chain charge at residues 266 and 268 are neutralized (from +1 at lysine to neutral at glutamine). Together, these results indicate that acetylation at Lys266/Lys268 can play a role in regulating the DNA binding activity of ER{alpha}.

K266/268Q ER{alpha}, But Not K266/268R ER{alpha}, Exhibits Increased Transactivation Activity in Cells
Finally, to determine whether the increased DNA binding activity observed in the EMSAs might lead to enhanced transactivation, we tested the activity of the K266/268Q and K266/268R mutant ER{alpha}s using a cell-based reporter gene assay. Briefly, HeLa cells grown in estrogen-free medium were transfected with a vector for the expression of wild-type, K266/268Q, or K266/268R ER{alpha} and a luciferase reporter construct containing two EREs upstream of the estrogen-regulated pS2 promoter. After treatment with vehicle or E2 for 18 h, the cells were collected, extracts were prepared, luciferase activity was measured (Fig. 8AGo), and relative ER{alpha} levels were determined by Western blotting (Fig. 8BGo; no differences were observed). The K266/268Q mutant, which mimics acetylated ER{alpha}, gave a 2-fold increase in reporter gene activity relative to wild-type ER{alpha} (Fig. 8AGo), suggesting that acetylation at Lys266/Lys268 can play a role in regulating the transcriptional activity of ER{alpha}. In contrast, the K266/268R mutant, which mimics unacetylated ER{alpha}, gave reporter gene activity similar to wild-type ER{alpha} (Fig. 8AGo). The lack of an inhibitory effect with the K266/268R mutant may be a consequence of the limited sensitivity of our reporter gene assays, as well as the extent of acetylation required for an observable effect. With regard to this latter point, note that with wild-type ER{alpha}, perhaps as few as 5% of the receptor molecules in the cells are acetylated (data not shown), whereas with the K266/268Q mutant, 100% of the receptor molecules are "acetylated." Collectively, our results demonstrate a good correlation between the increased DNA binding and transactivation activities of the K266/268Q mutant ER{alpha}, when compared with wild-type ER{alpha}.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
MATERIALS AND METHODS
 REFERENCES
 
Acetylation Modulates the Activity of ER{alpha}, Androgen Receptor, and Possibly Other Nuclear Receptors
In the studies described herein, we have shown that ER{alpha} is acetylated by p300 at Lys266 and Lys268 in an SRC-dependent manner (Figs. 1BGo, 3Go, and 4Go), with Lys268 being the major site of acetylation in full-length ER{alpha} (Fig. 4Go and Table 1Go). The extent of ER{alpha} acetylation is regulated by E2 both in vitro and in vivo (Figs. 1BGo and 6CGo). In addition, the acetylation of ER{alpha} is reversed by native cellular deacetylases, including TSA-sensitive enzymes (i.e. class I and II deacetylases) and NAD+-dependent/nicotinamide-sensitive enzymes (i.e. class III deacetylases, such as SIRT1) (Fig. 1Go, C and D). Furthermore, our results indicate that acetylation at Lys266 and Lys268 regulates the DNA binding and transcriptional activities of ER{alpha} (Figs. 7Go and 8Go). Collectively, our results implicate acetylation as modulator of the ligand-dependent gene regulatory activity of ER{alpha}. Ultimately, such regulation is likely to play a role in E2-dependent signaling outcomes in a variety of estrogen target tissues in both normal and pathological states.

To date, two other nuclear receptors have been shown to be targets for acetylation: AR (46) and thyroid hormone receptor (50). Acetylation of AR by p300/CBP and p300/CBP-associated factor decreases corepressor binding, increases coactivator binding, and increases ligand-dependent transactivation (45, 46). In addition, acetylation of AR may also regulate MAPK kinase kinase 1-induced apoptosis (51). Mutation of the AR acetylation sites also inhibits proper trafficking of the receptor, although it is not clear whether this is directly related to impaired acetylation of AR (47). Interestingly, histone deacetylase 1 has been shown to interact with AR in the absence of androgen and dissociate in the presence of androgen, suggesting that reversible acetylation might play a role in regulating activity of AR (51). In contrast to AR, little is known about the functional consequences of thyroid hormone receptor acetylation (50).

Alignment of human ER{alpha} with the ER{alpha}s from a variety of other species shows that Lys266 and Lys268 are highly conserved from amphibians through mammals (Fig. 5AGo). In addition, most non-orphan nuclear receptors typically have two or more, and as many as six, lysine residues located in the amino-terminal portion of the CTE, corresponding to the region where Lys266 and Lys268 are located in ER{alpha} (Fig. 5BGo). It is interesting to speculate that this region of nuclear receptors might represent a common target for acetylation. In this regard, note that this region includes the three lysine residues in AR that are acetylated by p300/CBP (Lys630, Lys632, and Lys633) (45, 46, 47) (Fig. 5BGo). Interestingly, human ERß lacks lysine residues homologous to Lys266 and Lys268 in ER{alpha} (Fig. 5BGo), fitting well with our observation that ERß is not acetylated by p300 under the same conditions that lead to acetylation of ER{alpha} (data not shown). These differences in acetylation by p300 may account for some of the functional differences that have been noted for ER{alpha} and ERß (7, 8, 9, 10, 11, 12, 13, 14, 15).

Acetylation of Lys266 and Lys268 Enhances the DNA Binding and Transactivation Activities of ER{alpha}
Our results demonstrate that acetylation of ER{alpha} at Lys266 and Lys268 by p300 enhances the DNA binding activity of ER{alpha} (Fig. 7Go), an effect that appears to be dependent on the neutralization of positive charges at those residues. In fact, substitution of Lys266 and Lys268 for glutamate (i.e. K266/268E), which has a negatively charged side chain, enhances ER{alpha} DNA binding activity to an even greater extent (~10-fold more than wild-type ER{alpha}; data not shown) than substitution for glutamine (i.e. K266/268Q; ~5-fold; Fig. 7Go). Because we lack structural information about this region, however, it is not clear whether Lys266 and Lys268 directly contact the DNA or are involved in critical intramolecular interactions that regulate the DNA binding activity of ER{alpha}. The former possibility seems less likely because one might expect the loss of positive charge at Lys266 and Lys268 upon acetylation to reduce, not enhance, interactions with negatively charged DNA. Furthermore, Lys266 and Lys268 are located outside of the core DBD in the CTE (Fig. 5AGo). Results from a recent study suggest that the CTE is required for the binding of ER{alpha} to imperfect EREs or half ERE sites and may be a target during the enhancement of ER{alpha} DNA binding by high mobility group B-1/2 proteins (17). Acetylation of Lys266 and Lys268 may play a role in modulating the structure of the CTE to enhance the DNA binding activity of ER{alpha}. Whether the increase in ER{alpha} DNA binding activity observed upon acetylation Lys266 and Lys268 is solely responsible for the concomitant increase in transcriptional activity has not yet been determined.

A Possible Role for Regulated Posttranslational Modification in Determining the Activity of ER{alpha}
The enzymes that regulate the acetylation state of ER{alpha} (i.e. the acetylases and deacetylases) are likely to play a key role in modulating the activity of ER{alpha}. p300 and its paralog CBP are potent acetylases that play multiple roles in ER{alpha}-dependent gene regulation (18, 22). Likewise, deacetylases have also been shown to play important roles in ER{alpha}-dependent gene regulation (52, 53, 54, 55, 56). Distinguishing the direct effects of these enzymes on ER{alpha} acetylation status from their effects on other transcription-related targets will require further investigation.

Interestingly, resveratrol, an activator of the NAD+-dependent deacetylase SIRT1 (57), has been shown to modulate estrogen-dependent signaling pathways and inhibit estrogen-dependent cell proliferation (58). Although direct effects of resveratrol on the activity of ER{alpha} are impossible to rule out (59, 60, 61, 62), it is interesting to speculate that perhaps some of the antagonistic actions of resveratrol on estrogen signaling relate to its ability to stimulate SIRT1 activity (i.e. resveratrol might enhance the deacetylation of ER{alpha} by SIRT1, thus reducing ER{alpha} DNA binding and transcriptional activities). The ability of SIRT1 to deacetylate ER{alpha} suggests a possible link between nuclear NAD+ metabolism, the regulation of ER{alpha} activity by acetylation, and cell proliferation. If this is the case, the acetylation status of ER{alpha}, as measured by acetylation-specific antibodies such as the ones described herein, might be a useful additional prognostic indicator for breast cancers.

Also of note with regard to the regulatory aspects of ER{alpha} posttranslational modification is that Lys266 and Lys268 in ER{alpha}, which are sites of acetylation, have recently been shown to be targets for SUMOylation as well (63). This suggests an intriguing interplay between these two posttranslational modifications in the regulation of ER{alpha} activity. As shown previously, multiple covalent posttranslational modifications of a single protein can interact functionally to add additional levels of regulatory control (40, 64, 65, 66, 67, 68). This possibility, and the others noted above, will be examined in future studies.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
REFERENCES
 
Chemicals
Acetyl CoA, E2, nicotinamide, NAD+, and TSA were from Sigma-Aldrich (St. Louis, MO). [3H]Acetyl CoA was from PerkinElmer Life and Analytical Sciences (Boston, MA).

Synthesis and Purification of Recombinant Proteins
FLAG-tagged wild-type human ER{alpha} and his6-tagged human p300 were expressed in Sf9 cells by using recombinant baculoviruses and purified as described previously (69, 70). Mutant human ER{alpha} cDNAs, including hER{alpha} {Delta}AB(180–595), hER{alpha} {Delta}DBD (1–180/269–595), hER{alpha} L540Q, and various hER lysine point mutants, were generated either by PCR or site-directed mutagenesis. The corresponding FLAG-tagged mutant ER{alpha} proteins were expressed in Sf9 cells by using recombinant baculoviruses and purified using FLAG M2 affinity chromatography as described for wild-type ER{alpha}. The his6-tagged mouse SIRT1 (also known as Sir2{alpha}) expression construct was provided by Shin-ichiro Imai (Washington University, St. Louis, MO). The corresponding protein was expressed in Escherichia coli and purified by standard nickel-nitrilotriacetic acid affinity chromatography. The GST-LBD(282–595) and GST-LBD(282–420) expression plasmids were provided by Benita Katzenellenbogen (University of Illinois, Urbana-Champaign, IL) and Richard Pestell (Georgetown University, Washington, DC), respectively. The corresponding GST-fusion proteins were expressed in E. coli and purified by standard glutathione-agarose affinity chromatography. GST-fused SRC2(RID/PID) was expressed in E. coli and purified by glutathione-agarose affinity chromatography as described previously (41). All purified proteins were frozen in aliquots in liquid N2 and stored at –80 C. Aliquots were analyzed by SDS-PAGE with Coomassie brilliant blue R-250 staining relative to BSA mass standards.

In Vitro ER{alpha} and Nucleosomal Core Histone Acetylation Assays
ER{alpha} and nucleosomal core histone acetylation reactions with [3H]acetyl CoA were carried out essentially as described previously (41). Briefly, ER{alpha} was incubated in the presence (Fig. 1BGo) or absence (all other figures) of salt-dialyzed chromatin, with or without p300, GST-SRC2(RID/PID), E2, and [3H]acetyl CoA as indicated in a final volume of 35 µl under reaction conditions described previously (71, 72). The chromatin was prepared by salt dialysis using a plasmid DNA template with four tandem EREs and was purified on sucrose gradients to remove free histones (41, 73). The reactions were incubated at 27 C for 30 min, and aliquots were analyzed by both 10 and 15% SDS-PAGE to resolve ER{alpha} and core histones, respectively. The proteins in the gels were detected by staining using Coomassie brilliant blue R-250, followed by fluorography. The 3H-labeled ER{alpha} and core histone bands were excised from the gel and quantified by liquid scintillation counting. Acetylation reactions with unlabeled acetyl CoA were carried out under similar reaction conditions; however, the acetylated target proteins were detected by Western blotting with antibodies to acetylated lysine (New England Biolabs, Ipswich, MA) or acetylated ER{alpha} (see description below). Mock acetylation reactions lacked acetyl CoA or GST-SRC2(RID/PID), as indicated.

In Vitro ER{alpha} Deacetylation Assays
Purified FLAG-tagged ER{alpha} was immobilized on FLAG M2-agarose resin and acetylated by p300 in the presence of [3H]acetyl CoA as described above to generate [3H]acetylated ER{alpha}. After extensive washing to remove the p300 and [3H]acetyl CoA, the ER{alpha} was eluted by using FLAG peptide, aliquoted, frozen in liquid N2, and stored at –80 C until use. For deacetylation reactions, [3H]acetylated ER{alpha} was incubated with HeLa cell nuclear extract or purified SIRT1 in deacetylation buffer [50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 4 mM MgCl2] for 40 min at 27 C in the presence or absence of TSA (10 µM), NAD+ (400 µM), and nicotinamide (4 mM) in a final volume of 100 µl as indicated. After the reactions were complete, the samples were incubated with FLAG M2-agarose resin for 2 h at 4 C to concentrate the ER{alpha} protein, followed by extensive washing. The resin was boiled in sodium dodecyl sulfate (SDS) loading solution, and the samples were resolved by SDS-PAGE with subsequent fluorography.

Mass Spectrometric Analysis of Acetylated ER{alpha}
In vitro acetylation of ER{alpha} was analyzed by quantitative mass spectrometry (42). ER{alpha} was acetylated by p300 in the presence of unlabeled acetyl CoA under the conditions described above. The ER{alpha} was separated from the other proteins in the reaction by SDS-PAGE with subsequent staining using Coomassie brilliant blue R-250. Gel slices containing the ER{alpha} were excised, treated with iodoacetamide to block oxidation of cysteines, washed, and dehydrated with acetonitrile. A mixture of 30% deuterium-acetic anhydride (D6-acetic anhydride) in 100 mM ammonium bicarbonate was added to the gel slices to acetylate all unmodified lysine residues in ER{alpha} with deuterated acetyl groups. After these chemical modifications, the ER{alpha} protein was digested with trypsin for 7 h at 37 C in the gel slices. Because of the complete acetylation of all lysine residues, trypsin cut only after arginine in these reactions. The resulting peptides contained light acetylation on lysines acetylated by p300 and heavy (deuterated) acetylation on all other lysines. This translated into a mass difference of –3 Da for acetylation visualized by MALDI-QqTOF mass spectrometry (43). The percent acetylation of the chemically identical, isotopically distinct peptides (i.e. heavy vs. light) was calculated directly from ratios of the intensities of the monoisotopic peaks. The specific sites of acetylation in the peptides showing acetyl CoA-dependent acetylation were confirmed by MS/MS analysis using a MALDI-ion trap mass spectrometer (42).

Generation of Acetylated ER{alpha} Antibodies
Rabbit antiacetylated Lys266/268 human ER{alpha} antiserum (AcK266/268-ER{alpha}) was generated by Covance Research Products (Denver, PA) using standard techniques for peptide immunogens. Briefly, a double acetylated peptide spanning amino acids 263 through 273 of human ER{alpha} (Arg-Met-Leu-acetyl-Lys-His-acetyl-Lys-Arg-Gln-Arg-Asp-Asp) was conjugated to KLH and used as an immunogen in rabbits. Non-acetylation-specific antibodies were depleted from the antiserum by adsorption to a nonacetylated peptide affinity matrix with subsequent collection of the unbound material. The antiserum was screened by ELISA and Western blotting using acetylated and unacetylated purified recombinant human ER{alpha}.

In Vivo ER{alpha} Acetylation Assays
MDA-MB-231 human breast cancer cells stably expressing FLAG-tagged human ER{alpha} (231/ ER{alpha} cells) (49) were grown in DME/F12 containing 10% charcoal-dextran stripped calf serum. 293T human kidney epithelial cells were grown in DMEM containing 10% FBS and were transfected with a vector (pCMV5) for the expression of FLAG-tagged wild-type or K266/268R human ER{alpha} using Fugene 6 transfection reagent (Roche Diagnostics, Indianapolis, IN) 18 h before subsequent treatments. Both the 231/ ER{alpha} cells and the transfected 293T cells were treated with 2 µM TSA and 5 mM nicotinamide in the presence or absence of 100 nM E2 for 2 h before collection. The cells were lysed in lysis buffer [10 mM Tris-HCl (pH 7.5), 0.5 M NaCl, 0.1% Nonidet P-40, 0.5 mM EDTA, 10% glycerol] supplemented with a complete protease inhibitor cocktail (Roche Diagnostics), TSA, and nicotinamide. The whole-cell lysates were diluted with an equal volume of incubation buffer [25 mM Tris-HCl (pH 7.9), 0.5% Triton X-100, 0.05% SDS, and 3 mM EDTA] and incubated with FLAG M2-agarose for 2 h at 4 C with gentle mixing. After the incubation, the resin was washed three times with wash buffer [20 mM Tris-HCl (pH 7.5), 300 mM NaCl, 10% glycerol, 1.5 mM MgCl2, and 0.2% Nonidet P-40]. After the final wash, the immunoprecipitated ER{alpha} was subjected to deacetylation or mock deacetylation in reactions containing 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 4 mM MgCl2 with or without purified SIRT1, and NAD+ as indicated. The reactions were incubated for 1 h at room temperature with gentle mixing, followed by extensive washing of the resin. After the final wash, the resin was boiled in SDS loading solution, and the samples were resolved by SDS-PAGE with subsequent Western blotting using an antibody to ER{alpha} or AcK266/268-ER{alpha}.

EMSAs
Purified recombinant wild-type or lysine point mutant ER{alpha}s, which were either unmodified, acetylated by p300, or mock acetylated as described above, were used for the EMSAs. EMSAs were performed essentially as described previously (74). Briefly, 20 nM ER{alpha} was incubated with 32P-end-labeled double-stranded oligonucleotide containing a consensus ERE sequence on ice for 20 min in the presence or absence of E2 (100 nM). The samples were analyzed on nondenaturing 4.8% polyacrylamide gels run in 1x TBE. Quantification of the shifted ER{alpha}:ERE complexes was done by phosphorimager analysis with ImageQuant, version 1.2, software (Molecular Dynamics, Sunnyvale, CA).

Transient Transfection Reporter Gene Assays
HeLa cells were grown in DME/F12 containing 10% charcoal-dextran stripped FBS. The cells were plated in six-well plates 12 h before transfection and reached approximately 70% confluence before transfection using Fugene 6 transfection reagent (Roche Diagnostics). Each well received the following combination of plasmid DNAs: 1) 5 ng of a pCMV5 vector for the expression of wild-type or mutant ER{alpha}, or 5 ng of an empty pCMV5 control vector, 2) 250 ng of an estrogen-responsive luciferase reporter construct containing two EREs upstream of the human pS2 (also known as TFF1) promoter (pGL3–2ERE-pS2-Luc), and 3) 100 ng of pCMVß, a constitutive ß-galactosidase expression vector used for normalization. Twelve hours after transfection, the cells were treated with vehicle or 10 nM E2 for an additional 18 h. Luciferase activity was measured in extracts from the transfected cells using a 96-well plate luminometer (LD400; Beckman Coulter, Fullerton, CA) and normalized to ß-galactosidase activity measured in the same extracts using the plate reader. To ensure reproducibility, each assay was run in duplicate, and each experiment was performed at least three times.


   ACKNOWLEDGMENTS
 
We thank the following people for their assistance with various aspects of this work: Tong Zhang, Miltos Kininis, Dave Wacker, Kristine Hope, Don Ruhl, Matt Gamble, and Raga Krishnakumar for critical reading of the manuscript; Christian Fritze for the antiacetylated ER{alpha} antibodies; Brian Chait for assistance with mass spectrometry; Richard Pestell, Shin-ichiro Imai, Benita Katzenellenbogen, and Michael Hottiger for plasmid DNA constructs; Mark Roberson for use of a luminometer; and Volker Vogt for advice and helpful discussions.


   FOOTNOTES
 
This work was supported by the American Cancer Society (RSG TBE-105130) and the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK058110) (to W.L.K.).

M.Y.K., E.M.W., Y.T.E.C., D.R.H., and W.L.K. have no potential conflicts of interests to declare with entities directly related to the material being published.

First Published Online February 23, 2006

Abbreviations: acetyl CoA, Acetyl coenzyme A; AR, androgen receptor; CBP, cAMP response element binding protein-binding protein; CTE, C-terminal extension; DBD, DNA-binding domain; E2, 17ß-estradiol; ER, estrogen receptor; GST, glutathione S-transferase; HNE, HeLa cell nuclear extract; LBD, ligand-binding domain; MALDI-QqTOF, matrix-assisted laser desorption/ionization-quadrupole-quadrupole-time of flight; MS/MS, mass spectrometry/mass spectrometry; NAD+, nicotinamide adenine dinucleotide; PID, p300/CBP interaction domain; RID, receptor interaction domain; SDS, sodium dodecyl sulfate; SIRT1, sirtuin 1; SRC, steroid receptor coactivator; TSA, trichostatin A.

Received for publication December 23, 2005. Accepted for publication February 13, 2006.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 

  1. Enmark E, Gustafsson JA 1999 Oestrogen receptors—an overview. J Intern Med 246:133-138[CrossRef][Medline]
  2. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: the second decade. Cell 83:835-839[CrossRef][Medline]
  3. Warner M, Nilsson S, Gustafsson JA 1999 The estrogen receptor family. Curr Opin Obstet Gynecol 11:249-254[CrossRef][Medline]
  4. Couse JF, Korach KS 1999 Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20:358-417[Abstract/Free Full Text]
  5. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA 2001 Mechanisms of estrogen action. Physiol Rev 81:1535-1565[Abstract/Free Full Text]
  6. Pettersson K, Gustafsson J 2001 Role of estrogen receptor ß in estrogen action. Annu Rev Physiol 63:165-192[CrossRef][Medline]
  7. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S 1998 Differential response of estrogen receptor {alpha} and estrogen receptor ß to partial estrogen agonists/antagonists. Mol Pharmacol 54:105-112[Abstract/Free Full Text]
  8. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS 1997 Differential ligand activation of estrogen receptors ER{alpha} and ERß at AP1 sites. Science 277:1508-1510[Abstract/Free Full Text]
  9. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor ß. Endocrinology 139:4252-4263[Abstract/Free Full Text]
  10. McInerney EM, Weis KE, Sun J, Mosselman S, Katzenellenbogen BS 1998 Transcription activation by the human estrogen receptor subtype ß (ERß) studied with ERß and ER{alpha} receptor chimeras. Endocrinology 139:4513-4522[Abstract/Free Full Text]
  11. Cowley SM, Parker MG 1999 A comparison of transcriptional activation by ER{alpha} and ERß. J Steroid Biochem Mol Biol 69:165-175[CrossRef][Medline]
  12. Delaunay F, Pettersson K, Tujague M, Gustafsson JA 2000 Functional differences between the amino-terminal domains of estrogen receptors {alpha} and ß. Mol Pharmacol 58:584-590[Abstract/Free Full Text]
  13. Jones PS, Parrott E, White IN 1999 Activation of transcription by estrogen receptor {alpha} and ß is cell type- and promoter-dependent. J Biol Chem 274:32008-32014[Abstract/Free Full Text]
  14. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA 2001 Estrogen receptor-ß potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 44:4230-4251[CrossRef][Medline]
  15. Cheung E, Schwabish MA, Kraus WL 2003 Chromatin exposes intrinsic differences in the transcriptional activities of estrogen receptors {alpha} and ß. EMBO J 22:600-611[CrossRef][Medline]
  16. Melvin VS, Roemer SC, Churchill ME, Edwards DP 2002 The C-terminal extension (CTE) of the nuclear hormone receptor DNA binding domain determines interactions and functional response to the HMGB-1/-2 co-regulatory proteins. J Biol Chem 277:25115-25124[Abstract/Free Full Text]
  17. Melvin VS, Harrell C, Adelman JS, Kraus WL, Churchill M, Edwards DP 2004 The role of the C-terminal extension (CTE) of the estrogen receptor {alpha} and ß DNA binding domain in DNA binding and interaction with HMGB. J Biol Chem 279:14763-14771[Abstract/Free Full Text]
  18. McKenna NJ, Lanz RB, O’Malley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321-344[Abstract/Free Full Text]
  19. Lee KC, Kraus WL 2001 Nuclear receptors, coactivators and chromatin: new approaches, new insights. Trends Endocrinol Metab 12:191-197[CrossRef][Medline]
  20. Leo C, Chen JD 2000 The SRC family of nuclear receptor coactivators. Gene 245:1-11[CrossRef][Medline]
  21. Glass CK, Rosenfeld MG 2000 The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121-141[Free Full Text]
  22. Kraus WL, Wong J 2002 Nuclear receptor-dependent transcription with chromatin. Is it all about enzymes? Eur J Biochem 269:2275-2283[Medline]
  23. Blobel GA 2000 CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 95:745-755[Free Full Text]
  24. Goodman RH, Smolik S 2000 CBP/p300 in cell growth, transformation, and development. Genes Dev 14:1553-1577[Free Full Text]
  25. Vo N, Goodman RH 2001 CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 276:13505-13508[Free Full Text]
  26. Blander G, Guarente L 2004 The Sir2 family of protein deacetylases. Annu Rev Biochem 73:417-435[CrossRef][Medline]
  27. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB 2003 Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737-749[CrossRef][Medline]
  28. Marks PA, Miller T, Richon VM 2003 Histone deacetylases. Curr Opin Pharmacol 3:344-351[CrossRef][Medline]
  29. Gray SG, Ekstrom TJ 2001 The human histone deacetylase family. Exp Cell Res 262:75-83[CrossRef][Medline]
  30. Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W 2004 Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci USA 101:2259-2264[Abstract/Free Full Text]
  31. Gu W, Roeder RG 1997 Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606[CrossRef][Medline]
  32. Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM 1999 Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98:675-686[CrossRef][Medline]
  33. Chen LF, Mu Y, Greene WC 2002 Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-{kappa}B. EMBO J 21:6539-6548[CrossRef][Medline]
  34. Chen L, Fischle W, Verdin E, Greene WC 2001 Duration of nuclear NF-{kappa}B action regulated by reversible acetylation. Science 293:1653-1657[Abstract/Free Full Text]
  35. Bannister AJ, Miska EA 2000 Regulation of gene expression by transcription factor acetylation. Cell Mol Life Sci 57:1184-1192[CrossRef][Medline]
  36. Sterner DE, Berger SL 2000 Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 64:435-459[Abstract/Free Full Text]
  37. Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S, Sardet C, Jin DY, Emiliani S, Benkirane M 2003 Post-activation turn-off of NF-{kappa}B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278:2758-2766[Abstract/Free Full Text]
  38. Kouzarides T 2000 Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19:1176-1179[CrossRef][Medline]
  39. Hassa PO, Haenni SS, Buerki C, Meier NI, Lane WS, Owen H, Gersbach M, Imhof R, Hottiger MO 2005 Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-{kappa}B-dependent transcription. J Biol Chem 280:40450-40464[Abstract/Free Full Text]
  40. Freiman RN, Tjian R 2003 Regulating the regulators: lysine modifications make their mark. Cell 112:11-17[CrossRef][Medline]
  41. Kim MY, Hsiao SJ, Kraus WL 2001 A role for coactivators and histone acetylation in estrogen receptor {alpha}-mediated transcription initiation. EMBO J 20:6084-6094[CrossRef][Medline]
  42. Smith CM, Gafken PR, Zhang Z, Gottschling DE, Smith JB, Smith DL 2003 Mass spectrometric quantification of acetylation at specific lysines within the amino-terminal tail of histone H4. Anal Biochem 316:23-33[CrossRef][Medline]
  43. Krutchinsky AN, Zhang W, Chait BT 2000 Rapidly switchable matrix-assisted laser desorption/ionization and electrospray quadrupole-time-of-flight mass spectrometry for protein identification. J Am Soc Mass Spectrom 11:493-504[CrossRef][Medline]
  44. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hopp T, Fuqua SA, Lopez GN, Kushner PJ, Pestell RG 2001 Direct acetylation of the estrogen receptor {alpha} hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 276:18375-18383[Abstract/Free Full Text]
  45. Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, Zhang X, Albanese C, Balk S, Chang C, Fan S, Rosen E, Palvimo JJ, Janne OA, Muratoglu S, Avantaggiati ML, Pestell RG 2003 Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23:8563-8575[Abstract/Free Full Text]
  46. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML, Pestell RG 2000 p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275:20853-20860[Abstract/Free Full Text]
  47. Thomas M, Dadgar N, Aphale A, Harrell JM, Kunkel R, Pratt WB, Lieberman AP 2004 Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts. J Biol Chem 279:8389-8395[Abstract/Free Full Text]
  48. Acevedo ML, Lee KC, Stender JD, Katzenellenbogen BS, Kraus WL 2004 Selective recognition of distinct classes of coactivators by a ligand-inducible activation domain. Mol Cell 13:725-738[CrossRef][Medline]
  49. Ediger TR, Kraus WL, Weinman EJ, Katzenellenbogen BS 1999 Estrogen receptor regulation of the Na+/H+ exchange regulatory factor. Endocrinology 140:2976-2982[Abstract/Free Full Text]
  50. Lin HY, Hopkins R, Cao HJ, Tang HY, Alexander C, Davis FB, Davis PJ 2005 Acetylation of nuclear hormone receptor superfamily members: thyroid hormone causes acetylation of its own receptor by a mitogen-activated protein kinase-dependent mechanism. Steroids 70:444-449[CrossRef][Medline]
  51. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua SA, Jaffray E, Hay RT, Palvimo JJ, Janne OA, Pestell RG 2002 Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol 22:3373-3388[Abstract/Free Full Text]
  52. Margueron R, Duong V, Bonnet S, Escande A, Vignon F, Balaguer P, Cavailles V 2004 Histone deacetylase inhibition and estrogen receptor {alpha} levels modulate the transcriptional activity of partial antiestrogens. J Mol Endocrinol 32:583-594[Abstract]
  53. Leong H, Sloan JR, Nash PD, Greene GL 2005 Recruitment of histone deacetylase 4 to the N-terminal region of estrogen receptor {alpha}. Mol Endocrinol 19:2930-2942[Abstract/Free Full Text]
  54. Kawai H, Li H, Avraham S, Jiang S, Avraham HK 2003 Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor {alpha}. Int J Cancer 107:353-358[CrossRef][Medline]
  55. Liu XF, Bagchi MK 2004 Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. J Biol Chem 279:15050-15058[Abstract/Free Full Text]
  56. Kurtev V, Margueron R, Kroboth K, Ogris E, Cavailles V, Seiser C 2004 Transcriptional regulation by the repressor of estrogen receptor activity via recruitment of histone deacetylases. J Biol Chem 279:24834-24843[Abstract/Free Full Text]
  57. Sinclair D 2005 Sirtuins for healthy neurons. Nat Genet 37:339-340[Medline]
  58. Le Corre L, Chalabi N, Delort L, Bignon YJ, Bernard-Gallon DJ 2005 Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res 49:462-471[CrossRef][Medline]
  59. Gehm BD, McAndrews JM, Chien PY, Jameson JL 1997 Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94:14138-14143[Abstract/Free Full Text]
  60. Gehm BD, Levenson AS, Liu H, Lee EJ, Amundsen BM, Cushman M, Jordan VC, Jameson JL 2004 Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. J Steroid Biochem Mol Biol 88:223-234[CrossRef][Medline]
  61. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM 2000 Resveratrol acts as a mixed agonist/antagonist for estrogen receptors {alpha} and ß. Endocrinology 141:3657-3667[Abstract/Free Full Text]
  62. Bouras T, Fu M, Sauve AA, Wang F, Quong AA, Perkins ND, Hay RT, Gu W, Pestell RG 2005 SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem 280:10264-10276[Abstract/Free Full Text]
  63. Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L 2005 Sumoylation of the estrogen receptor {alpha} hinge region regulates its transcriptional activity. Mol Endocrinol 19:2671-2684[Abstract/Free Full Text]
  64. Yang XJ 2005 Multisite protein modification and intramolecular signaling. Oncogene 24:1653-1662[CrossRef][Medline]
  65. Gronroos E, Hellman U, Heldin CH, Ericsson J 2002 Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 10:483-493[CrossRef][Medline]
  66. Desterro JM, Rodriguez MS, Hay RT 1998 SUMO-1 modification of I{kappa}B{alpha} inhibits NF-{kappa}B activation. Mol Cell 2:233-239[CrossRef][Medline]
  67. Fischle W, Wang Y, Allis CD 2003 Histone and chromatin cross-talk. Curr Opin Cell Biol 15:172-183[CrossRef][Medline]
  68. Berger SL 2002 Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12:142-148[CrossRef][Medline]
  69. Kraus WL, Kadonaga JT 1998 p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev 12:331-342[Abstract/Free Full Text]
  70. Kraus WL, Kadonaga JT 1999 Ligand- and cofactor-regulated transcription with chromatin templates. In: Picard D, ed. Steroid/nuclear receptor superfamily: a practical approach. Oxford, UK/New York: Oxford University Press; 167-189
  71. Kraus WL, Manning ET, Kadonaga JT 1999 Biochemical analysis of distinct activation functions in p300 that enhance transcription initiation with chromatin templates. Mol Cell Biol 19:8123-8135[Abstract/Free Full Text]
  72. Manning ET, Ikehara T, Ito T, Kadonaga JT, Kraus WL 2001 p300 forms a stable, template-committed complex with chromatin: role for the bromodomain. Mol Cell Biol 21:3876-3887[Abstract/Free Full Text]
  73. Jeong SW, Lauderdale JD, Stein A 1991 Chromatin assembly on plasmid DNA in vitro. Apparent spreading of nucleosome alignment from one region of pBR327 by histone H5. J Mol Biol 222:1131-1147[CrossRef][Medline]
  74. Kraus WL, Montano MM, Katzenellenbogen BS 1994 Identification of multiple, widely spaced estrogen-responsive regions in the rat progesterone receptor gene. Mol Endocrinol 8:952-969[Abstract/Free Full Text]

NURSA Molecule Pages Link:

Nuclear Receptors:   TRα  |  TRβ  |  RARα  |  RARβ  |  RARγ  |  PPARα  |  PPARδ  |  PPARγ  |  VDR  |  RXRα  |  RXRβ  |  RXRγ  |  ERα  |  ERβ  |  GR  |  MR  |  PR  |  AR
Coregulators:   Sirt1  |  p300  |  SRC-1  |  GRIP1  |  AIB1
Ligands:   17β-Estradiol



This article has been cited by other articles:


Home page
 EndocrinologyHome page
A. Sanchez-Pacheco, O. Martinez-Iglesias, M. Mendez-Pertuz, and A. Aranda
Residues K128, 132, and 134 in the Thyroid Hormone Receptor-{alpha} Are Essential for Receptor Acetylation and Activity
Endocrinology, November 1, 2009; 150(11): 5143 - 5152.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
S.-W. Guo
Epigenetics of endometriosis
Mol. Hum. Reprod., October 1, 2009; 15(10): 587 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. C. Wu and Y. Zhang
Minireview: Role of Protein Methylation and Demethylation in Nuclear Hormone Signaling
Mol. Endocrinol., September 1, 2009; 23(9): 1323 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Zhang, J. G. Berrocal, K. M. Frizzell, M. J. Gamble, M. E. DuMond, R. Krishnakumar, T. Yang, A. A. Sauve, and W. L. Kraus
Enzymes in the NAD+ Salvage Pathway Regulate SIRT1 Activity at Target Gene Promoters
J. Biol. Chem., July 24, 2009; 284(30): 20408 - 20417.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Q. Zhou, P. G Shaw, and N. E Davidson
Epigenetics meets estrogen receptor: regulation of estrogen receptor by direct lysine methylation
Endocr. Relat. Cancer, June 1, 2009; 16(2): 319 - 323.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
K. H. Kim, J. M. Yoon, A H. Choi, W. S. Kim, G. Y. Lee, and J. B. Kim
Liver X Receptor Ligands Suppress Ubiquitination and Degradation of LXR{alpha} by Displacing BARD1/BRCA1
Mol. Endocrinol., April 1, 2009; 23(4): 466 - 474.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
C. Atsriku, D. J. Britton, J. M. Held, B. Schilling, G. K. Scott, B. W. Gibson, C. C. Benz, and M. A. Baldwin
Systematic Mapping of Posttranslational Modifications in Human Estrogen Receptor-{alpha} with Emphasis on Novel Phosphorylation Sites
Mol. Cell. Proteomics, March 1, 2009; 8(3): 467 - 480.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
N. B. Berry, M. Fan, and K. P. Nephew
Estrogen Receptor-{alpha} Hinge-Region Lysines 302 and 303 Regulate Receptor Degradation by the Proteasome
Mol. Endocrinol., July 1, 2008; 22(7): 1535 - 1551.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
S. C. Roemer, J. Adelman, M. E. A. Churchill, and D. P. Edwards
Mechanism of high-mobility group protein B enhancement of progesterone receptor sequence-specific DNA binding
Nucleic Acids Res., June 1, 2008; 36(11): 3655 - 3666.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
T. Hattori, F. Coustry, S. Stephens, H. Eberspaecher, M. Takigawa, H. Yasuda, and B. de Crombrugghe
Transcriptional regulation of chondrogenesis by coactivator Tip60 via chromatin association with Sox9 and Sox5
Nucleic Acids Res., May 1, 2008; 36(9): 3011 - 3024.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C. Wang, M. J. Powell, V. M. Popov, and R. G. Pestell
Acetylation in Nuclear Receptor Signaling and the Role of Sirtuins
Mol. Endocrinol., March 1, 2008; 22(3): 539 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. Aoyagi and T. K. Archer
Nicotinamide Uncouples Hormone-Dependent Chromatin Remodeling from Transcription Complex Assembly
Mol. Cell. Biol., January 1, 2008; 28(1): 30 - 39.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
W.-x. Zhao, M. Tian, B.-x. Zhao, G.-d. Li, B. Liu, Y.-y. Zhan, H.-z. Chen, and Q. Wu
Orphan Receptor TR3 Attenuates the p300-Induced Acetylation of Retinoid X Receptor-{alpha}
Mol. Endocrinol., December 1, 2007; 21(12): 2877 - 2889.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
J. R. Schultz-Norton, V. A. Gabisi, Y. S. Ziegler, I. X. McLeod, J. R. Yates, and A. M. Nardulli
Interaction of estrogen receptor {alpha} with proliferating cell nuclear antigen
Nucleic Acids Res., August 1, 2007; 35(15): 5028 - 5038.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C. M. Silva and M. A. Shupnik
Integration of Steroid and Growth Factor Pathways in Breast Cancer: Focus on Signal Transducers and Activators of Transcription and Their Potential Role in Resistance
Mol. Endocrinol., July 1, 2007; 21(7): 1499 - 1512.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. R. Schultz-Norton, K. A. Walt, Y. S. Ziegler, I. X. McLeod, J. R. Yates, L. T. Raetzman, and A. M. Nardulli
The Deoxyribonucleic Acid Repair Protein Flap Endonuclease-1 Modulates Estrogen-Responsive Gene Expression
Mol. Endocrinol., July 1, 2007; 21(7): 1569 - 1580.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
H. Matsuda, B. D. Paul, C. Y. Choi, and Y.-B. Shi
Contrasting Effects of Two Alternative Splicing Forms of Coactivator-Associated Arginine Methyltransferase 1 on Thyroid Hormone Receptor-Mediated Transcription in Xenopus laevis
Mol. Endocrinol., May 1, 2007; 21(5): 1082 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Simonsson, M. Kanduri, E. Gronroos, C.-H. Heldin, and J. Ericsson
The DNA Binding Activities of Smad2 and Smad3 Are Regulated by Coactivator-mediated Acetylation
J. Biol. Chem., December 29, 2006; 281(52): 39870 - 39880.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data File
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, M. Y.
Right arrow Articles by Kraus, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, M. Y.
Right arrow Articles by Kraus, W. L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals